Showing 3031-3040 of 3315 results for "".
- New Automated Method Developed for Corneal Nerve Fiber Tortuosity Analysishttps://modernod.com/news/new-automated-method-developed-for-corneal-nerve-fiber-tortuosity-analysis/2477369/The Intelligent Medical Imaging (iMED) Group at the Cixi Institute of Biomedical Engineering, Ningbo Institute of Materials Technology and Engineering (CNITECH) of the Chinese Academy of Sciences proposed a fully automated method for image-level corneal nerve fiber tortuosity estimation, contribu
- Kala Pharmaceuticals Announces Statistically Significant Results in STRIDE 3 Trial of Dry Eye Disease Drug Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-statistically-significant-results-in-stride-3-trial-of-dry-eye-disease-drug-eysuvis/2477360/Kala Pharmaceuticals announced positive topline results from STRIDE 3, a phase 3 clinical trial evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. STRIDE 3 met b
- The American Optometric Association (AOA) Partners With Lyft To Offer Free Rides To Get A Comprehensive Eye Examhttps://modernod.com/news/the-american-optometric-association-aoa-partners-with-lyft-to-offer-free-rides-to-get-a-comprehensive-eye-exam/2477334/The American Optometric Association (AOA), the leading authority on quality care and an advocate for our nation’s health, representing more than 30,000 doctors of optometry, announced that it is working with Lyft, the transportation network, to offer free rides to people in select cities in
- Zeiss Concludes Acquisition of Saxonia Systems and Creates Carl Zeiss Digital Innovation in Dresden, Germanyhttps://modernod.com/news/zeiss-concludes-acquisition-of-saxonia-systems-and-creates-carl-zeiss-digital-innovation-in-dresden-germany/2477335/Zeiss has concluded its acquisition of Saxonia Systems AG, a specialist for customized software solutions. The fully acquired company will now operate as Carl Zeiss Digital Innovation. The new unit will support the Zeiss segments with their digital projects and play a leading role in terms of inn
- Study Advances Development of Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/study-advances-development-of-gene-therapy-for-x-linked-retinitis-pigmentosa/2477321/A new study marks a significant advance in developing a gene therapy for X-linked retinitis pigmentosa, a hereditary disease that leads to severe sight loss in young males. Researchers at Bascom Palmer Eye Institute, the Department of Ophthalmology a
- Schwind Hosts 18th International User Meeting in Hamburghttps://modernod.com/news/schwind-hosts-18th-international-user-meeting-in-hamburg/2477306/A new attendance record was set at the 18th International Schwind User Meeting. Schwind reported that about 260 attendees from more than 50 countries met in Hamburg, Germany, January 23-25, 2020. The Schwind user fami
- Calvin Roberts, MD, Named President and CEO of Lighthouse Guildhttps://modernod.com/news/calvin-roberts-md-named-president-and-ceo-of-lighthouse-guild/2477286/Calvin Roberts, MD, has been elected President and CEO of Lighthouse Guild. Dr. Roberts will leave his position as Senior Vice President and Chief Medical Officer, Eye Care, at Bausch Health Companies, on March 31. Dr. Roberts i
- Staar Surgical Announces Strategic Cooperation Agreement with Senshinkai Eye Institute in Japanhttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-senshinkai-eye-institute-in-japan/2477276/Staar Surgical announced that it entered a strategic cooperation agreement with Senshinkai Eye Institute (SEI), an eye care group with five locations in Japan. The agreement includes volume commitments for the company’s implantable collamer lenses (ICLs), ICL surgeon training and certification, t
- Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairshttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-michelle-senchyna-phd-as-vice-president-clinical-development-and-medical-affairs/2477271/Aerie Pharmaceuticals announced the appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, MD, MBA, Aerie’s Chief Research & Development Officer. Dr. Senchyna will lead and direct the clinical development and
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.